# A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer

> **NCT05699135** · — · TERMINATED · sponsor: **Pfizer** · enrollment: 150 (actual)

## Conditions studied

- Urinary Bladder Neoplasms
- Bladder Cancer
- Bladder Tumors
- Urothelial Carcinoma

## Interventions

- **DRUG:** Avelumab first-line maintenance

## Key facts

- **NCT ID:** NCT05699135
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-09
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 150 (ACTUAL)
- **Why stopped:** The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns.
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05699135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05699135, "A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05699135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*